NCT01421056 - Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Alzheimer's Disease

Interventions

DRUG

CHF 5074 1x

oral tablet, 1x, once a day in the morning for 24 weeks

DRUG

CHF 5074 2x

oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks

DRUG

CHF 5074 3x

oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks

Trial Locations (6)

78757

Senior Adults Specialty Research, Austin

07724

Memory Enhancement Center of America, Inc., Eatontown

08831

Memory Center of New Jersey, Inc., Monroe Twp

08755

Memory Enhancement Center of NJ, Inc., Toms River

Unknown

Clinica Santa Maria, Div Neurologia, Castellanza

Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milan

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY